DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for migraine, familial hemiplegic, 3 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMigraine, familial hemiplegic, 3 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for migraine, familial hemiplegic, 3 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel alpha subunit 1 (SCN1A) — SCN1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3beta,14beta,17beta,25rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7DTD · 3.3 Å · ligand (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en (9Z9). Experimental structure, not a prediction.
What the evidence adds up to
Familial hemiplegic migraine is a rare monogenic subtype of migraine with aura, and three genes have been identified for it. Knock-in mice carrying human pathogenic FHM1 mutations show behavioural, electrophysiological, and neurobiological characteristics consistent with prevailing views of migraine physiology. These genetic models may help unravel triggering mechanisms and identify prophylactic targets, but no specific drug is tested or proposed in these abstracts.
Hemiplegic migraine occurs in sporadic or familial forms, differentiated only by family history. Treatment trials are anecdotal; verapamil and acetazolamide have shown promise, but no controlled trial data are reported. The molecular mechanisms of migraine attack remain unclear, and constructed hypothetical signalling pathways for FHM type I have only identified key molecules for further study, not validated targets.
Migraine affects approximately 15% of Western populations, with a significant genetic component. Seven loci with significant linkage to migraine with or without aura have been identified on chromosomes 1q31, 4q24, 6p12.2-21.1, 11q24, 14q21.2-q22.3, 15q11-q13 and Xq24-28. The identification of susceptibility genes for common migraine is complicated by clinical and genetic heterogeneity. No drug is mentioned in the genetic linkage studies.
What is still missing: controlled treatment trials for hemiplegic migraine, validated molecular targets from the signalling pathway analyses, and identification of how genetic variants interact with environmental factors to produce migraine attacks. Patient stratification by genotype is not yet possible for common migraine, and no prophylactic therapy has been tested in a randomised trial for this rare subtype.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Neurology · 2007 · 70 citations
Genetic Models of Migraine
AbstractMigraine is a common, disabling, complex brain disorder, presenting in attacks that may have up to 3 phases: a prodromal phase, the aura phase, and the headache phase. The pathogenesis of the aura and headache phases is reasonably well understood, but the mechanism by which migraine attacks are triggered is unknown. Most likely, migraineurs have a genetically determined reduced threshold for migraine triggers. Identifying "threshold genes" and deciphering their function will help to unravel the triggering mechanisms for migraine attacks. Familial hemiplegic migraine is a rare monogenic subtype of migraine with aura. Three genes have been identified for familial hemiplegic migraine. Recently, knock-in mice carrying human pathogenic FHM1 mutations were generated, which show behavioral, electrophysiological, and neurobiological characteristics in line with prevailing views of migraine physiological processes. Genetic migraine models will be useful in unraveling the triggering mechanisms for migraine attacks and in identifying novel migraine prophylactic targets and therapies.
Sporadic and Familial Hemiplegic Migraine: Diagnosis and Treatment
AbstractHemiplegic migraine is a rare subtype of migraine with aura associated with transient hemiplegia. The weakness is caused by motor aura. Hemiplegic migraine is the only headache syndrome associated with known genetic mutations and serves as a model for understanding more common varieties of migraine. Because the phenotype includes striking yet transient neurological signs and symptoms, it is imperative that clinicians know the differential diagnosis to rule out possible secondary etiologies when treating patients with hemiplegic spells. Hemiplegic migraine occurs with equal prevalence in either a sporadic or familial form differentiated only by family history. Thus far, treatment trials are anecdotal, although verapamil and acetazolamide have shown promise.
Apnoeic spells following general anaesthesia in a patient with familial hemiplegic migraine
AbstractHemiplegic migraine is an unusual variant of migraine, characterised by a temporary hemiparesis or hemiplegia associated with headache. We report a patient with hemiplegic migraine who developed atypical migraine with apnoeic spells, aphasia and hemiparesis following general anaesthesia. We review the clinical features of hemiplegic migraine and the considerations for its anaesthetic management.
Journal of Neurology & Stroke · 2017 · 2 citations
Familial Hemiplegic Migraine Type I: The Molecular Signaling Pathway
AbstractMigraine is a multifactorial disease, manifested by intense bouts of recurrent headaches.Molecular mechanisms of migraine attack are not clear.In this study, we carried out the analysis of molecular processes in the pathogenesis of a rare hereditary form of migrainefamilial hemiplegic migraine type I. Constructed hypothetical signaling pathways allowed us to understand the causes of a migraine attack and identify key molecules and signaling pathways for further experimental and clinical studies.
The Molecular Genetics of Migraine: Toward the Identification of Responsible Genes
AbstractMigraine is a complex debilitating neurovascular disease affecting approximately 15% of the Western populations. Familial clustering, twin studies and segregation analyses suggest that migraine has a significant genetic component, but the number of genes involved remains unclear. The progress in migraine genetics has recently jumped ahead with the identification of genes responsible for Familiar Hemiplegic Migraine (FHM), a rare subtype of migraine with aura showing autosomal dominant mode of inheritance. Nevertheless, the knowledge about common types of migraine has been particularly rewarding and recently, seven loci with significant linkage to migraine with or without aura have been identified on 1q31, 4q24, 6p12.2-21.1, 11q24, 14q21.2-q22.3, 15q11-q13 and Xq24-28, suggesting the presence of migraine susceptibility genes in these regions. Identification of genes predisposing to the more common and genetically complex forms of migraine has been complicated by clinical and genetic heterogeneity of the disease. The major challenge in the coming years facing biomedical research of migraine is the identification of disease-susceptibility genes and the understanding of how migraine risk can be influenced by the interaction of these variants with each other and with specific environmental factors in order to provide individuals with clinically-useful diagnostic, prognostic and therapeutic information. This paper briefly summarizes the previous knowledge and highlights some recent developments in the complex genetic nature of migraine. Keywords: Familial hemiplegic migraine, migraine with aura, migraine without aura
Journal of Neurology & Stroke · 2017 · 0 citations · open access
AbstractMigraine is a multifactorial disease, manifested by intense bouts of recurrent headaches. Molecular mechanisms of migraine attack are not clear. In this study, we carried out the analysis of molecular processes in the pathogenesis of a rare hereditary form of migrainefamilial hemiplegic migraine type I. Constructed hypothetical signaling pathways allowed us to understand the causes of a migraine attack and identify key molecules and signaling pathways for further experimental and clinical studies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
